Danone (DN) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
21 Dec, 2025Executive summary
Q1 2025 delivered a strong start with like-for-like sales up 4.3%, driven by balanced volume mix (+1.9%) and price (+2.4%), with all regions and categories contributing positively.
Broad-based growth was seen across all geographies, with particularly strong momentum in China, North Asia & Oceania (+9.9%) and Latin America (+9.0%).
Strategic focus on health-centric and science-based innovation, diversified channels, and premiumization underpinned resilience and above-sector growth.
Financial highlights
Q1 2025 reported sales were €6,844m, up 0.8% year-over-year, with LFL growth partially offset by negative currency (-0.8%) and scope (-3.0%) effects.
Like-for-like sales growth of 4.3% comprised 1.9% from volume/mix and 2.4% from pricing.
All main categories grew: EDP +3.7%, Specialized Nutrition +5.3%, Waters +4.1% LFL.
Outlook and guidance
2025 guidance confirmed: like-for-like sales growth of 3–5% and recurring operating income to grow faster than sales.
Confidence in multiple growth engines and strategic positioning in high-growth, health-focused categories.
Latest events from Danone
- H1 2026 saw strong sales, margin gains, and portfolio expansion; 2026 guidance reaffirmed.DN
Q2 2026 - Growth driven by health trends, innovation, and digital transformation, with strong future outlook.DN
23rd annual dbAccess Global Consumer Conference - Q1 2026 delivered +2.7% LFL sales growth, but reported sales fell -2.0% on currency impacts.DN
Q1 2026 - 4.5% LFL sales growth, margin up 44bps, and strong cash flow despite currency and recall impacts.DN
Q4 2025 - Q3 2025 sales rose 4.8% LFL, driven by volume/mix and strong China, North Asia & Oceania growth.DN
Q3 2025 - Q3 2024 like-for-like sales up 4.2%, with all regions and categories contributing to growth.DN
Q3 2024 - 4.0% LFL sales growth, margin up, cash flow +11%, 2024 guidance confirmed.DN
Q2 2024 - Targets 3–5% sales growth and €3bn free cash flow by 2028, led by science and Medical Nutrition.DN
CME 2024 - Achieved 4.3% LFL sales growth, margin gains, and record €3.0bn free cash flow in FY 2024.DN
Q4 2024